NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the area needed. The company announced clinical tests that showed the company's proprietary exosomes "significantly reduced inflammation" in cell, both untreated and those treated with a commercially available product.